O'DonnellJ.S, TengM.W.L., SmythM.J.Cancer immunoediting and resistance to T cell-based immunotherapy. Nature Reviews Clinical Oncology, 16:151–167 (2019).
2.
LiK., TandurellaJ.A., GaiJ., et al.Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Cell Cancer, 40:1374–1391 (2022).
3.
ChowA., PericaK., KlebanoffC.A., et al.Clinical implications of T cell exhaustion for cancer immunotherapy. Nature Reviews Clinical Oncology, 19:775–790 (2022).
4.
Rhodes FordB., VignaliP.D.A., RittenhouseN.L., et al.Tumor microenviron-mental signals reshape chromatin landscapes to limit the functional potential of exhausted T cells. Science Immunology, 7(74): eabj9123 (2022).
MorrisonA.H., ByrneK.T., VonderheideR.H.Immunotherapy and prevention of pancreatic cancer. Trends in Cancer, 4(6);419428 (2018).
7.
GulhatiP., SchalckA., JiangS., et al.Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer, Nature Cancer. 4:62–80 (2023).
8.
LiK., ZhangA., LiX., et al.Advances in clinical immunotherapy for gastric cancer. Biochimica et Biophysica Acta - Reviews on Cancer, 1876(2):188615 (2021).
9.
EphraimR., FraserS., NurgaliK., et al.Checkpoint markers and tumor microenvironment: What do we know?. Cancers (Basel), 14(15):3788 (2022).
10.
MärklF., HuynhD., EndresS., et al.Utilizing chemokines in cancer immunotherapy. Trends in Cancer, 8(8):670–682 (2022).
11.
KirchhammerN., TrefnyM.P., Auf der MaurP., et al.Cancer immunotherapies: emerging treatment strategies adapted to the tumor microenvironment. Cancer Immunotherapy, 14(670): eabo3605 (2022).
12.
DuanX., ChanC., LinW. Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy. Angewandte Chemie International Edition in English, 8(3):670–680 (2019).
13.
RedaM., NgamcherdtrakulW., NelsonM.A., et al.Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment. Nature Communications, 13: 4261 (2022).
14.
ZhongY., DuS., DongaY. mRNA delivery in cancer immunotherapy. Acta Pharmaceutica Sinica B, 13(4):1348–1357 (2023).
15.
ErfaniA., DiazA.E., DoyleP.S.. Hydrogel-enabled, local administration and combinatorial delivery of immunotherapies for cancer treatment. Materials Today, 65:227–243 (2023).
16.
JongeriusC., VermeulenL., EgmondM.V.Behavioral factors to modulate immunotherapy efficacy in cancer. Frontiers in Immunology, 13: 1066359 (2022).
